Drug Development

Multiple dose study initiated for AEOL 10150 in patients with amyotrophic lateral sclerosis

Published in Drug Week, November 11th, 2005

Aeolus Pharmaceuticals, Inc., (AOLS.OB) announced that its follow-on phase I multiple dose study of AEOL 10150 in patients diagnosed with amyotrophic lateral sclerosis, also referred to as ALS or Lou Gehrig disease, has been initiated.

The first three ALS patients in the initial six-patient cohort received 40 mg of AEOL 10150 or placebo twice-daily (80 mg/day total) for 6 days, followed by a single injection of 40 mg on the seventh day, and, based on initial observations, there have been no serious adverse events.

Following the completion of the second half of the first cohort (i.e. the second three ALS patients), it is planned that two additional...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry